Should Methoxytyramine Routinely Be Included in the Guidelines for Biochemical Assessment of Pheochromocytomas and Paragangliomas?
Status PubMed-not-MEDLINE Jazyk angličtina Země Spojené státy americké Médium electronic-ecollection
Typ dokumentu úvodníky
PubMed
39896939
PubMed Central
PMC11784605
DOI
10.1016/j.aace.2024.11.005
PII: S2376-0605(24)00132-9
Knihovny.cz E-zdroje
Zobrazit více v PubMed
Mustafa K., Zadeh S., Culver S.A. Dopamine-secreting carotid body paraganglioma in a patient with SDHB mutation. AACE Clin Case Rep. 2024;10(3):109–112. PubMed PMC
Lenders J.W., Duh Q.Y., Eisenhofer G., et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–1942. PubMed
Mete O., Asa S.L., Gill A.J., Kimura N., de Krijger R.R., Tischler A. Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr Pathol. 2022;33(1):90–114. PubMed
Tischler A.S., Kimura N., McNicol A.M. Pathology of pheochromocytoma and extra-adrenal paraganglioma. Ann N Y Acad Sci. 2006;1073:557–570. PubMed
Eisenhofer G., Pamporaki C., Lenders J.W.M. Biochemical assessment of pheochromocytoma and paraganglioma. Endocr Rev. 2023;44(5):862–909. PubMed
Lenders J.W., Eisenhofer G., Mannelli M., Pacak K. Phaeochromocytoma. Lancet. 2005;366(9486):665–675. PubMed
Jhawar S., Arakawa Y., Kumar S., et al. New insights on the genetics of pheochromocytoma and paraganglioma and its clinical implications. Cancers. 2022;14(3):594. PubMed PMC
Nolting S., Bechmann N., Taieb D., et al. Personalized management of pheochromocytoma and paraganglioma. Endocr Rev. 2022;43(2):199–239. PubMed PMC
Richter S., Qiu B., Ghering M., et al. Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine. Endocr Relat Cancer. 2022;29(4):213–224. PubMed PMC
van Faassen M., Bischoff R., Eijkelenkamp K., de Jong W.H.A., van der Ley C.P., Kema I.P. In matrix derivatization combined with LC-MS/MS results in ultrasensitive quantification of plasma free metanephrines and catecholamines. Anal Chem. 2020;92(13):9072–9078. PubMed PMC
Eisenhofer G., Goldstein D.S., Sullivan P., et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab. 2005;90(4):2068–2075. PubMed
Jha A., de Luna K., Balili C.A., et al. Clinical, diagnostic, and treatment characteristics of SDHA-related metastatic pheochromocytoma and paraganglioma. Front Oncol. 2019;9:53. PubMed PMC
Taieb D., Wanna G.B., Ahmad M., et al. Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants. Lancet Diabetes Endocrinol. 2023;11(5):345–361. PubMed PMC
Taieb D., Nolting S., Perrier N.D., et al. Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement. Nat Rev Endocrinol. 2024;20(3):168–184. PubMed
Pamporaki C., Berends A.M.A., Filippatos A., et al. Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort. Lancet Digit Health. 2023;5(9):e551–e559. PubMed PMC
